AbbVie Inc. stock analysis: shares at a two-year high with strong cash flow, a 50.69 P/E and a 117% payout ratio. Model signal: Hold.
Pharmaceuticals
-
-
Eli Lilly and Company stock analysis: 38.6% revenue growth, a two-year high and a 46.15 P/E. See how the scores lead to a Hold signal.
-
Zoetis Inc. stock analysis: elite margins, a 13.1 P/E and stalled growth. See how the Quality, Growth and Opportunity scores add up to a Buy signal.
-
PharmaceuticalsUS Stocks
Hims & Hers Jumps 10% in a Day, but Losses, an FTC Lawsuit and Thin Cash Flow Keep the Model at Hold
Hims & Hers Health stock analysis: revenue up 38%, but losses, an FTC lawsuit and a faulty cash flow figure keep the model at Hold.
-
FeaturedPharmaceuticalsUS Stocks
United Therapeutics Rallies on Its Tyvaso IPF Filing – a 95/100 Quality Score at 19.4 Times Earnings
United Therapeutics stock analysis: UTHR rallies on its Tyvaso IPF filing with a 95/100 Quality score and a 19.40 P/E. Why the model rates it a Buy.
-
PharmaceuticalsUS Stocks
Merck Looks Strong at the Top Line, but the Stock Price Leaves Little Room for Error
Merck & Company, Inc. stock analysis: discover key fundamentals, sector insights, and forecast trends for smart healthcare investments.
-
Pfizer, Inc. stock analysis: comprehensive review of financials, earnings, and investment potential in the pharmaceutical sector.